ArticleFrontiers in aging neuroscience2026
Increasing daily step count in mild cognitive impairment: a 12-month randomised controlled trial.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite numerous studies confirming the beneficial effects of physical activity on cognitive function, there is a lack of randomised controlled trials involving long-term, continuous monitoring of physical activity that assess the effect of step-based intervention on cognition-related outcomes. Therefore, this study evaluated whether increasing daily step count improves cognitive performance and brain health markers in individuals with mild cognitive impairment (MCI). Methods: Caucasian, community-dwelling participants aged 50-70 years with MCI and smartphone ownership were recruited for this randomised, controlled, parallel-group study, and assigned to intervention or control groups. The intervention group aimed to achieve ≥10,000 steps daily, with no individualised or baseline-adjusted activity targets, whereas controls maintained usual activity. Physical activity was monitored by wrist-worn trackers over 12 months. Cognitive function was measured using the Montreal Cognitive Assessment (MoCA) and the Cambridge Neuropsychological Test Automated Battery. Brain volume, cardiometabolic, and neurodegeneration biomarkers were assessed. Results: 198 participants were recruited between July 2021 and September 2022 and assigned to the intervention ( Discussion: In adults with MCI and moderate baseline activity, a small increase in daily step count over 12 months led to modest changes in MoCA scores, while evidence from the broader cognitive battery was limited and largely exploratory. No effect on brain volume, peripheral neurodegeneration markers, body composition, or metabolism was noted (Trial registry: https://drks.de; identifier: DRKS00020943).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.